The valve is adjustable gravitational valve that features an integrated fixed pressure differential valve during the most active time of the day, according to the company. The fixed pressure differential valve addresses posture changes.
“We are very pleased to be able to continue to provide healthcare teams with new and innovative solutions,” president Chuck DiNardo said in a news release. “With our strong partnership with Miethke comes an impactful collaborative effort to bring better Hydrocephalus solutions to patients, such as the new M.blue valve.”
It is estimated that over one million people in the U.S. live with hydrocephalus, according to the Hydrocephalus Association. Shunt therapy is the golden standard for treating it, but implantations of shunts have had high failure rates, caused multiple revisions and surgeries for people with the condition.
“The patient is our priority and we will continue to invest in research and development to create better solutions. Our focus on Hydrocephalus valves creates an expertise and openness to future developments that allows us to serve in a way that will improve the lives that we touch,” said Christoph Miethke, CEO and founder of MIETHKE, the manufacturer of Hydrocephalus valves for Aesculap.
